Zinger Key Points
- Cronos Group is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited.
- The Toronto-based company owns roughly 10% of Vitura’s common shares, formerly known as Cronos Australia.
- Get Monthly Picks of Market's Fastest Movers
Cronos Group Inc. CRON CRON announced on Tuesday that it is expanding distribution into the Australian market with its first shipment of cannabis flower to Vitura Health Limited.
The Toronto-based company owns roughly 10% of Vitura's common shares, formerly known as Cronos Australia, and will supply cannabis for Vitura.
"Supplying the Australian market, which has grown significantly in the past three years, is a great milestone for Cronos as we aim to enter and expand within international markets," said Mike Gorenstein, the company's chairman, president and CEO. "We look forward to working closely with our partners at Vitura to provide patients with high-quality cannabis products and establish our presence in Australia as a trusted cannabis partner."
In its press release, the company cited Australia's Therapeutic Goods Administration's data, highlighting that medical cannabis approvals to new patients through an Authorized Prescriber have continued to grow in 2023, with the aggregate of all new patients reported in the first six months amounting to 307,846 compared to 137,111 new patients over the same period in 2022.
According to a recent survey of 1,000 participants conducted by consumer insights company Antenna, around 8% of Australians are using medical marijuana either occasionally or regularly.
Meanwhile, a bill introduced this past November in the New South Wales Parliament would allow the cultivation of up to six cannabis plants for use and sharing them with friends and is supported by a majority of Australians.
Missed the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.
Don't miss out on the green rush!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.